Header

UZH-Logo

Maintenance Infos

External validation of a risk model of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma


Schwenkglenks, Matthias; Bendall, Kate Louise; Pfeil, Alena M; Szabo, Zsolt; Pettengell, Ruth (2013). External validation of a risk model of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma. Leukemia & Lymphoma, 54(11):2426-2432.

Abstract

Febrile neutropenia (FN) is a common and serious complication of chemotherapy treatment. Clinical risk models may help to identify patients at high risk of FN but must undergo external validation before implementation in medical practice. Therefore, this study externally validated previously published clinical models of FN occurrence during chemotherapy in 240 patients with non-Hodgkin lymphoma by using an independent observational dataset (n = 1829). The models demonstrated predictive ability, and validation criteria for predicting any cycle of FN were partially met but a larger than expected decrease in performance was noted (area under the receiver operating characteristic curve was 0.71 in the validation dataset and 0.83 in the training dataset). Age, weight, baseline white blood cell count and planned chemotherapy parameters were confirmed to predict FN risk. Chemotherapy dose reductions, dose delays and colony-stimulating factor use were confirmed as risk modifiers during treatment. Further work is needed to improve the predictive ability of FN risk models.

Abstract

Febrile neutropenia (FN) is a common and serious complication of chemotherapy treatment. Clinical risk models may help to identify patients at high risk of FN but must undergo external validation before implementation in medical practice. Therefore, this study externally validated previously published clinical models of FN occurrence during chemotherapy in 240 patients with non-Hodgkin lymphoma by using an independent observational dataset (n = 1829). The models demonstrated predictive ability, and validation criteria for predicting any cycle of FN were partially met but a larger than expected decrease in performance was noted (area under the receiver operating characteristic curve was 0.71 in the validation dataset and 0.83 in the training dataset). Age, weight, baseline white blood cell count and planned chemotherapy parameters were confirmed to predict FN risk. Chemotherapy dose reductions, dose delays and colony-stimulating factor use were confirmed as risk modifiers during treatment. Further work is needed to improve the predictive ability of FN risk models.

Statistics

Citations

Dimensions.ai Metrics
4 citations in Web of Science®
4 citations in Scopus®
3 citations in Microsoft Academic
Google Scholar™

Altmetrics

Downloads

29 downloads since deposited on 30 Dec 2013
12 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > Epidemiology, Biostatistics and Prevention Institute (EBPI)
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2013
Deposited On:30 Dec 2013 09:02
Last Modified:16 Feb 2018 18:47
Publisher:Informa Healthcare
ISSN:1026-8022
OA Status:Green
Publisher DOI:https://doi.org/10.3109/10428194.2013.780287
PubMed ID:23452152

Download

Download PDF  'External validation of a risk model of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma'.
Preview
Content: Accepted Version
Language: English
Filetype: PDF
Size: 241kB
View at publisher